{"name":"Mineralys Therapeutics Inc.","slug":"mineralys-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"Mineralys Therapeutics Inc. is a biopharmaceutical company focused on developing novel therapies for the treatment of hypertension and related cardiovascular diseases. The company's lead candidate, lorundrostat, is in Phase 2 clinical trials, demonstrating its commitment to advancing innovative treatments in this therapeutic area.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":132009000,"netIncome":-154651000,"cash":172921000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"lorundrostat Dose 1","genericName":"lorundrostat Dose 1","slug":"lorundrostat-dose-1","indication":"Congestive heart failure","status":"phase_3"}]}],"pipeline":[{"name":"lorundrostat Dose 1","genericName":"lorundrostat Dose 1","slug":"lorundrostat-dose-1","phase":"phase_3","mechanism":"Lorundrostat is a selective, reversible inhibitor of 11β-HSD1.","indications":["Congestive heart failure"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxONGtHV0lCaXZiWDVkR0NyRF9LdzB5TnA3Y0J4UTExb3ZBWVpSVXI4V3Exc1VmVkp3SjFoaVZCWlRYaFBDTU1kM09FRzhteXoyZGF4NDNoaFdrRnRPdHkxVmxQWHJPa25xdFdKc3VHdXE3LVJiZnd0OWtaaFhHcUViRmhoYkRLSWM1NzV2STY0Z3hFNFlPdzlkOUIzXzhfd2hjdFFkN2hDRGtqN1czM2NjYTd5dV9SdmVhUlkwNWE5MjA?oc=5","date":"2026-04-08","type":"pipeline","source":"Stock Titan","summary":"Mineralys Therapeutics (NASDAQ: MLYS) details 2026 virtual meeting, board elections - Stock Titan","headline":"Mineralys Therapeutics (NASDAQ: MLYS) details 2026 virtual meeting, board elections","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxQVG0yS1BLSmh6WW5zamd5dzIyNW9ZcUduX3VfQTEzcVZwa0NYdGpYRlNhN2ZoMzBCNHJHMVpDb3FHU2xkM1gwMVR5VUpOUWJNc0V2NzI3VDJHVVV1UDIyYjZKZElsQ0FNVG1YbXM1a0VFNldPYzBXdTdrMXctVldMVi01Z2pJaUFKYWlPajhvYTFtYjJ0MkFMNlhUcTlkWF9XREhCZ21BeFA2RS00TndoXzRDMldWcFVrNjJTN05RSDFjOWt3UlpFaUNiVFBUWVhkdFVzUjgxcjZVR1liVVlYZEc1NzZiQ0VXcVBab2JBWENHOC1BOThxSHNyd0RjUm_SAf8BQVVfeXFMUFRtMktQS0poelluc2pneXcyMjVvWXFHbl91X0ExM3FWcGtDWHRqWEZTYTdmaDMwQjRyRzFaQ29xR1NsZDNYMDFUeVVKTlFiTXNFdjcyN1QyR1VVdVAyMmI2SmRJbENBTVRtWG1zNWtFRTZXT2MwV3U3azF3LVZXTFYtNWdqSWlBSmFpT2o4b2ExbWIydDJBTDZYVHE5ZFhfV0RIQmdtQXhQNkUtNE53aF80QzJXVnBVazYyUzdOUUgxYzlrd1JaRWlDYlRQVFlYZHRVc1I4MXI2VUdZYlVZWGRHNTc2YkNFV3FQWm9iQVhDRzgtQTk4cUhzcndEY1Jv?oc=5","date":"2026-04-06","type":"pipeline","source":"The Manila Times","summary":"Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors - The Manila Times","headline":"Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxORkppWDdGekpWQ1dZWGRtVzdmaDc0ZW42cGkxYkVPb19pTEVnNTRKTFk4MXFIUDMyZklNakNNckYwNjFaWVlsOVY0T3BqdURMYUMwTmg2MDFNdVdpV3BKNi1pc3BKY3pMdDZXOHluWDdZZ1BQVWw0bURJSXVjeXN2Z1BtVzBseGlHYWlTWDBhOFUxZWh3TXBKdU1nNUE2MmNWek56eE9CMThvWFBWWGVnUTNvc2FCLXRScmthOW91ZFlZdV91TlB0QW9waW5WOU90Mkl6LXpGTHYtbWhDSUVRbm5uYlNaNC11ZmZoNFYxVWtBSXpvc0NhOXU3RUZKWFRsZzhyU0Jjc0Q3c2NiOHIzR0NVMzI?oc=5","date":"2026-03-26","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS) and Terns Pharmaceuticals (TERN) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS) and Terns Pharmaceuticals (TERN)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-24","type":"pipeline","source":"The Manila Times","summary":"Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer - The Manila Times","headline":"Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNcnl1ek1oTmZ1dUl2cTg3cjJJbHlUdzQyajhCakhpWldyeHVFNjhwZ0hhYVVlZWp4YVVNdkhJaDRVU2ttaEJ2Qm1McWJaSUhrOHplaGZjQ2VNODFYTHFFTGlMWThuaXZ2a1Jjbmo0Q0o0bTZmeWZ6d2FMNHpxbFF2ZFNodlo5aldpaldZanY0Y3pldzFmdFlHd1ZIcnIwRGhOM29ITGFYUGZsSlRwMjVfQXN2cjhndmVka0E?oc=5","date":"2026-03-13","type":"regulatory","source":"Seeking Alpha","summary":"Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval (MLYS) - Seeking Alpha","headline":"Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval (MLYS)","sentiment":"positive"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQLUQ1OE55Mk9aVVkycjFzRXE0dXNPVFVxbk9iYU9vdGFQQnp5Rk0zVFNucVlfUkxLc3FzVHBxT1RDYUl6cExZbjlOaGNhMlloaWEyVXRCM2M3V2lfYncyUk55b1RWNVhnb1UtTjBodU5wZ0lIX3VLNTU1a0JiZUZ5TkJDcFJfeXNubDZHMklTNWYxQlNRWlFZ?oc=5","date":"2026-01-15","type":"deal","source":"BioWorld News","summary":"Muted and missing M&As: JPM deals absent in 2026 - BioWorld News","headline":"Muted and missing M&As: JPM deals absent in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTFBrLXNJcWNXZnVDNzJlMUNIQ0I1eVJ6ZUlWN2xKU0NCaXFsVXJZWVVYYS0xTmw1dEZ3dFBYZE05Ymt3ZkNUa2l1bThPaGpXaTlpRFlFQ1d4MnpyX3JHYkVIU05DN3Q?oc=5","date":"2025-09-18","type":"pipeline","source":"The Pharma Letter","summary":"Mineralys Therapeutics - The Pharma Letter","headline":"Mineralys Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNR1d2dmJ4aVdVSUJlOG1XRTVpbWZMNFFMMWxuTkZVQ0ZTczNTME9ieVZsOVZJNTJCWmdmdWdyUDVSTVBlWFh5amdSTkVmWTNEQXJRVHkxNWhHbnQtLU50VlNRWDNvTVNoUmJpT2F5THQ4eXFZaTRINkxJeEcwQ1RGUWFLTFpfcTFpUGZUdlFfMjVEX25yaWNXeG9hR21zVkx6MTZoZ0xpS0hCbUVvZHJv?oc=5","date":"2025-09-03","type":"trial","source":"Seeking Alpha","summary":"Mineralys: Soaring As Rival's Hypertension Data Falls Short - Buy The Next Dip (MLYS) - Seeking Alpha","headline":"Mineralys: Soaring As Rival's Hypertension Data Falls Short - Buy The Next Dip (MLYS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPLW1vZ3JJeXFOenJnNnFCYW02b1FmWVRBNmEtdGFTN29nOE5tdEFObTI0RnYzTkQxUHJVTGlyeEhsaS02WEg2UUV0YWFlaWFjVXhkX2o3OGwzWmg3b1NHWm5XbEJvS3RLQWtleVZEeGVJTjBMY05fME9KVW1vbElRWGd3TDZhU1ZJSm90SVpaU0Jkczk3bHo2UDFfZXo?oc=5","date":"2025-09-02","type":"pipeline","source":"The Pharma Letter","summary":"Q&A with Jon Congleton, CEO of Mineralys Therapeutics - The Pharma Letter","headline":"Q&A with Jon Congleton, CEO of Mineralys Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPWGFITUJlcVQxcW9jaE54MVplRllGaVozd0wxQldPZUZIaEVNdWVnNld3NWM3T1J5VlBFdWp5MThGbm9BSFNJanlYdllVX2xQbnNyRWhaVGpCZEJtVFJMeGhiZWJIZFdWd0EtRFNYdXh6MFFpZkJ2eDk3SFVSVk8xa3djLUhSS2lqbG5GNGVIZ0xIenVBVFd5RXZTY0ZUQjlDOUtacG5HUjNqWV8yZ1YydGlyR3RvbWRET19vcUdmWkoxSFdqLXV2c1NOSHFsZXdHT0wyX2JZWFdjTE1rNTBrZHpTV2FqaVE2N3c?oc=5","date":"2025-09-02","type":"regulatory","source":"Benzinga","summary":"Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket - Benzinga","headline":"Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxOeVJySFd0cUhvSXpGc0F4cGZjdGVjZ2FpUXlTMFZzXzQySlJVbG5Ec3Z5eFJhS29pcldrLXVXbVI3RGZ6YjItcEdKUmdBLTBlS0xXVHdYdWZfMV81TUlBV2Y4aUhJYnRXb3R1TTVSLW1jSmZmRmtfMVR6d1V1VUhvckRObmZ2ckgyLXdjYVVGS2N1dnU4TGVlZVhVU2xnSHR2YzVuX3VYNG1ZQnAzVmdaSHFnYUM0Rng3UU15akNIdWdMeHlFVlpfTFJ0ZWxtMzNnNzlsS1B0ODE3cFROUTNmNm0xVjhzTjRTV0FZR9IB8gFBVV95cUxPdlZsc0Y3NVFxWjB6dVJwMUhsVkpmRC02bXk1Ym9YemNrWTRtT29yZnMxQWQyUGEtZWFJbVVnNTVrTlNCdFExajZOam9OVEJUa0ZYYzZfNElqQjQ0X1BKQTAweU15WEozWE9MYV9PclhaMEgteXdKUmFYcDVCZDZmWTRxMVNwUFJWaGt0dVltM2N1TEhfSGlsNUVNNjJYNW5zcjlzVF9HcFFmaUFDempnVFlMWmtEUWFtdENfNDJkN3BGcW9udFJvZ25iN01PSVNSWUt3akRRTXlXemdJRXhQNzVLTmU3WG5QMHNac2lTd1E0dw?oc=5","date":"2025-08-05","type":"pipeline","source":"simplywall.st","summary":"Mineralys Therapeutics CFO & Secretary Adam Levy Sells 36% Of Holding - simplywall.st","headline":"Mineralys Therapeutics CFO & Secretary Adam Levy Sells 36% Of Holding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPOFZvTmNxY3BidnhUSEhRRU0weHdHRndxNXFYQ0JFUHJGOFRkTXpMYWYyWjlaSTVFZXoydG5pR3F4U3RSN1RSNHdPdEctV01GMU9FM1RYS1VJNDJmZGppUENzTzAtX1NGWWhHS1RNZVRrZHU4TWtzSmxERHh3bVdTaFo5cVdvVHhxZnFtZ1YtRjA?oc=5","date":"2025-03-10","type":"trial","source":"statnews.com","summary":"Mineralys Therapeutics stock soars on blood pressure drug data - statnews.com","headline":"Mineralys Therapeutics stock soars on blood pressure drug data","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":132009000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-154651000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":172921000,"cashHistory":[],"totalAssets":661806000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}